S100A10 and Stroke: Thus, treatment with AEVs derived from cultured ischemic astrocytes with anti-inflammatory properties and the reduction of C3d and increase of S100A10 further downregulated C3d and increased S100A10 marker expression in reactive astrocytes in the peri-infarct area of chronic phase rats subjected to MCAO, which thereby facilitated stroke recovery.